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Kirby M, Heydarian M, Wheatley A, McCormack DG, Parraga
G. Evaluating bronchodilator effects in chronic obstructive pulmonary
disease using diffusion-weighted hyperpolarized helium-3 magnetic res-
onance imaging. J Appl Physiol 112: 651–657, 2012. First published
December 8, 2011; doi:10.1152/japplphysiol.01295.2011.—The objec-
tive of this study was to evaluate the regional effects of bronchodilator
administration in chronic obstructive pulmonary disease (COPD)
using hyperpolarized helium-3 (3He) MRI apparent diffusion coeffi-
cient (ADC). Ten COPD ex-smokers provided written, informed
consent and underwent diffusion-weighted, hyperpolarized 3He MRI,
spirometry, and plethysmography before and 25  2 min after
bronchodilator administration. Pre- and postsalbutamol whole-lung
(WL) ADC maps were generated and registered together to identify
the lung regions containing the 3He signal at both time points, and
mean ADC within those regions of interest (ROI) was determined for
a measurement of previously ventilated ROI ADC (ADCP). Lung ROI
with 3He signal at both time points was used as a binary mask on
postsalbutamol WL ADC maps to obtain an ADC measurement for
newly ventilated ROI (ADCN). Postsalbutamol, no significant differ-
ences were detected in WL ADC (P  0.516). There were no
significant differences between ADCN and ADCP postsalbutamol
(P  1.00), suggesting that the ADCN lung regions were not more
emphysematous than the lung ROI participating in ventilation before
bronchodilator administration. Postsalbutamol, a statistically signifi-
cant decrease in ADCP (P  0.01) was detected, and there were
significant differences between ADCP in the most anterior and
most posterior image slices (P  0.02), suggesting a reduction in
regional gas trapping following bronchodilator administration.
Regional evaluation of tissue microstructure using hyperpolarized
3He MRI ADC provides insights into lung alterations that accom-
pany improvements in regional 3He gas distribution after broncho-
dilator administration.
apparent diffusion coefficients; chronic obstructive pulmonary disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is character-
ized by progressive expiratory flow limitation that develops as
a result of the lung’s inflammatory response to inhaled toxic
gases and particles, primarily from tobacco smoke (37). Air-
flow limitation may be caused by a number of factors, such as
lumen occlusion via mucus plugs (14); structural alteration of
the airway wall, resulting in encroachment of the airway wall
into the airway lumen (15, 24); and/or a loss of elastic recoil
within the lung parenchyma due to emphysematous tissue
destruction that leads to reduced tethering forces stabilizing the
airways at forced expiration (36). The prolongation of the time
constants for lung emptying results in numerous physiological
and functional consequences, including hyperinflation and gas
trapping, as well as ventilation abnormalities that lead to many
of the disabling symptoms associated with COPD, such as
dyspnea and limitation of exercise capacity (16, 34).
Administration of short-acting -agonist bronchodilators is
first-line therapy in the symptomatic management of COPD
(35), and this is thought to decrease airway smooth muscle
tone, thereby improving lung emptying during expiration (28).
Whereas improvements in airflow limitation and reductions in
lung hyperinflation following bronchodilator administration
have been shown previously (2, 29, 30), there is still little
understanding about the regional nature of the bronchodilator
response in COPD. In this regard, pulmonary MRI using
hyperpolarized helium-3 (3He) provides high spatial and tem-
poral resolution in in vivo images of 3He gas distribution
within the lung in COPD subjects (3, 4, 8, 17, 19, 22, 23, 25,
38). In COPD ex-smokers, we previously observed significant
improvements in the regional distribution of 3He gas after
bronchodilator administration (18); however, it was unclear
whether these regional improvements were related to physio-
logical or symptomatic improvements. The measurement of the
3He apparent diffusion coefficient (ADC) has been demon-
strated to be highly reproducible (6, 26, 33) and is sensitive to
changes in the lung microstructure and airspace size (38, 43,
44), correlating with spirometry (39), diffusing capacity of
carbon monoxide (11), multislice computed tomography (CT)
measurements of emphysema (5), as well as lung surface-area
measurements (41). 3He MRI ADC measurements are also age
dependent (9) and reflect the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) classification of disease
severity (8) and smoking history (11) and detect gas trapping
within the dependent lung regions in COPD (7).
We hypothesized that the improvements in 3He gas distri-
bution, which we observed previously after bronchodilation in
COPD, may be the direct source of symptomatic relief follow-
ing therapy. To help test this hypothesis, here, we aimed to
evaluate hyperpolarized 3He MRI ADC as a surrogate of the
extent of emphysematous tissue destruction within the newly
ventilated regions of interest [ROI (ADCN); postbronchodila-
tor] and to evaluate regional gas trapping following broncho-
dilator administration. We evaluated lung microstructural mea-
surements using regional 3He MRI ADC in COPD before and
after bronchodilator administration (18), after developing im-
age registration/segmentation methods for quantifying ADC in
the lung regions’ newly ventilated postbronchodilator.
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MATERIALS AND METHODS
Subjects. All subjects were enrolled in a 3He MRI study of the
acute effects of salbutamol administration (18), in which written,
informed consent to the protocol, approved by the local research
ethics board and Health Canada, was provided, and the study was
compliant with the Personal Information Protection and Electronic
Documents Act (Canada) and the Health Insurance Portability and
Accountability Act (USA). COPD subjects were enrolled who were
ex-smokers between the ages of 50 and 85, with a clinical diagnosis
of COPD, and were categorized according to the GOLD criteria (37)
with a smoking history of at least 10 pack years. Subjects were
required to withhold short-acting bronchodilators the morning of their
study visit. Prebronchodilator MRI was performed immediately fol-
lowing pulmonary function tests, and postbronchodilator MRI was
performed 25 min (2 min) after administration of 400 g salbuta-
mol, inhaled via a spacer device. Digital pulse oximetry was used to
measure arterial oxygen saturation (SaO2) during scanning sessions,
and a hypoxic adverse event was defined as a decrease in SaO2 below
88% at any time during imaging. Study withdrawal was required when
SaO2 decreased to 80% for 10 s or longer.
Pulmonary function tests. Spirometry was performed using an ndd
EasyOne spirometer (ndd Medizintechnik AG, Zurich), reporting
forced expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC), with a minimum of three acceptable spirometry maneuvers,
with the best FEV1 and FVC selected for analysis, according to
American Thoracic Society guidelines. Total lung capacity (TLC),
inspiratory capacity (IC), functional residual capacity (FRC), and
residual volume (RV) were measured using body plethysmography
(Medgraphics, St. Paul, MN).
Image acquisition. MRI was performed on a whole-body 3.0 Tesla
Excite 12.0 MRI system [General Electric Healthcare (GEHC),
Waukesha, WI] with broadband imaging capability, as described
previously (40). All helium imaging used a whole-body gradient set
with maximum gradient amplitude of 1.94 G/cm and a single-channel
rigid elliptical transmit/receive chest coil (Rapid Biomedical GmbH,
Germany). The basis frequency of the coil was 97.3 MHz, and
excitation power was 3.2 kW using an AMT 3T90 radiofrequency
(RF) power amplifier (GEHC, Waukesha, WI). Subjects were posi-
tioned supine in the MR scanner, and SaO2 was used to monitor
arterial blood oxygenation levels during all MRI maneuvers. For both
1H and 3He MRI, subjects were instructed by a pulmonary function
technologist to inhale a gas mixture from a 1.0-liter Tedlar bag
(Jensen Inert Products, Coral Springs, FL) from FRC, and image
acquisition was performed under breath-hold conditions (a period of
8–15 s).
Coronal proton (1H) MRI was performed prior to hyperpolarized
3He MRI with subjects scanned during breath-hold after inspiration of
a 1.0-liter 4He/N2 gas mixture using the whole-body RF coil and 1H
fast-spoiled, gradient-recalled echo sequence [16 s total data acquisi-
tion, repetition time (TR)/echo time (TE)/flip angle  4.7 ms/1.2
ms/30°, field-of-view (FOV)  40  40 cm, matrix 256  128, 14
slices, 15 mm slice thickness, 0 gap], as described previously (12).
Prior to 3He MRI, a polarizer system (Helispin, GEHC, Durham,
NC) was used to polarize 3He gas to 30–40%. As described previ-
ously (21), hyperpolarized 3He MRI diffusion-weighted images were
acquired in breath-hold after inspiration of a 1.0-liter 3He/N2 mixture
(5 mL/kg body wt) using a fast gradient-echo method with centric
k-space sampling. Two interleaved images were acquired (14 s total
data acquisition, TR/TE/flip angle  7.6 ms/3.7 ms/8°, FOV  40 
40 cm, matrix 128  128, seven slices, 30 mm slice thickness), with
and without additional diffusion sensitization [strength (G)  1.94
G/cm, rise and fall time  0.5 ms, gradient duration  0.46 ms,
interval   1.46 ms, duration and strength (b)  1.6 s/cm2].
Image analysis. 3He MRI ADC analysis was performed using
MATLAB R2007b (MathWorks, Natick, MA). To ensure that ADC
was generated for voxels corresponding to ventilated lung regions,
k-means cluster algorithm (21), developed previously for 3He MRI
segmentation (13, 18, 20), was applied to the nondiffusion-weighted
images to obtain a binary mask for each slice. The resulting binary
masks were applied to the corresponding nondiffusion-weighted im-
ages, and the ADC maps were generated on a voxel-by-voxel basis
according to Eq. 1
ADC
1
b
lnS0S  (1)
where S0 is the segmented nondiffusion-weighted image, S is the
diffusion-weighted image, and b  1.6 s/cm2.
An overview of the 3He MRI analysis methodology is provided in
Fig. 1. To minimize the potential for differences in the levels of
inspiration between pre- and postsalbutamol imaging, extensive
coaching was performed among the breath-hold scans for all subjects.
Pre- and postsalbutamol ADC maps were registered using landmark-
based image registration. Briefly, the center slice, defined as the slice
that clearly showed the carina and primary bronchi, was identified in
the nondiffusion-weighted images for each imaging time point and
displayed side by side. A fiducial marker was identified on both the
pre- and postsalbutamol 3He images, based on the carina, and a
translation operation was used to transform the postsalbutamol image
for registration with the corresponding landmark in the presalbutamol
image. The resultant transformation was then applied to the 3He ADC
maps for all slices. The trachea and visible major airways were
removed semiautomatically using a ROI (function ROIPOLY in
MATLAB), permitting ADC calculation within the lung parenchyma.
Whole-lung (WL) ADC values were determined for each slice and
then averaged to obtain a single ADC for each subject. Following
registration of the pre- and postsalbutamol ADC maps, the lung ROI
with 3He signal at both time points were identified as the intersection
of the pre- and postsalbutamol maps; mean ADC within those ROI
was generated for each slice and then averaged to obtain a previously
ventilated ADC (ADCP) for both presalbutamol and postsalbutamol
conditions. Lung ROI with a 3He signal at both time-points were used
as a binary ventilation mask on the postsalbutamol ADC maps to
calculate mean ADC in ADCN. To ensure that ADC estimates were
generated for the ADCN postsalbutamol and to minimize the contri-
bution of patient movement or breath-hold mismatch between imag-
ing time-points, we used a morphological closing algorithm on the
postsalbutamol ADC maps (function imclose in MATLAB) with a
disk-shaped structuring element, with radius 1. The resultant binary
masks were applied to the ADC maps of the ADCN postsalbutamol,
and mean ADCN was determined.
Statistical methods. All statistical analyses were performed using
IBM SPSS Statistics 19.0 (IBM, Chicago, IL). Multivariate ANOVA
and repeated measures ANOVA were performed for comparison of
pre- and postsalbutamol pulmonary function measurements. Statistical
comparisons of mean pre- and postsalbutamol WL ADC and ADCP
measurements were performed using a two-way mixed-design re-
peated measures ANOVA with imaging time point (pre- and postsal-
butamol) treated as the within-subject factor and subject treated as the
between-subjects factor. Comparison between ADCP and ADCN post-
salbutamol was also performed using a two-way mixed-design re-
peated measures ANOVA with ROI (ADCP or ADCN postsalbuta-
mol), treated as the within-subject factor and subject treated as the
between-subjects factor. Anatomical differences in ADC within the
regions of the lung ventilated at both time-points were quantified by
determining the mean ADC in the most posterior slice and by
calculating the absolute difference in ADC between the most anterior
and the most posterior slice (AP). Comparisons between mean ADC
in the most posterior slice and AP pre- and postsalbutamol were
determined using a two-tailed Wilcoxon signed-rank t-test. Spearman
correlation coefficients were used to determine the relationship be-
tween ADC and pulmonary function measurements. In all statistical
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analyses, results were considered significant when the probability of
making a Type I error was 5% (P  0.05).
RESULTS
All subjects completed both scanning sessions, and there
were no serious or severe breath-hold-related or other adverse
events reported, nor were there any other adverse events that
required subjects to withdraw from the study. Table 1 shows
study subject demographics and mean pulmonary function
measurements (n 3 Stage II, n 6 Stage III, and n 1 Stage
IV) before and after salbutamol administration. Statistically
significant postsalbutamol changes were observed for FEV1
(P  0.007), TLC (P  0.02), FRC (P  0.02), and RV (P 
0.02).
Figure 2 shows representative 3He ADC maps pre- and
postsalbutamol for a single subject and identifies visually
obvious alterations in gas distribution. Figure 3A shows mean
pre- and postsalbutamol 3He MRI ADC measurements for all
subjects. There was no significant difference detected for WL
ADC postsalbutamol (P  0.516). As shown in Table 2, no
significant correlations were detected between the change in
WL ADC postsalbutamol and the change in pulmonary func-
tion measurements. However, there was a significant correla-
tion between presalbutamol WL ADC and the change in IC
(r  0.68, P  0.03).
Figure 4 shows two representative COPD subjects: the WL
pre- and postsalbutamol ADC maps and the maps postsalbu-
tamol. There was no statistically significant difference between
ADCN and ADCP postsalbutamol (ADCP  0.506  0.072
cm2/s, ADCN  0.504  0.082 cm2/s, P  1.00), nor were
there any significant interactions between the ADCN and
ADC
P
postsalbutamol (P  0.18), indicating no significant
change in ADC within the ADCN lung areas following admin-
istration of salbutamol.
For ADCP measurements, there was a statistically significant
decrease detected postsalbutamol (P  0.013; Fig. 3A). As
shown in Fig. 3B, the mean ADC in the most posterior slice
was significantly lower postsalbutamol (P  0.049). In addi-
tion, AP was significantly higher postsalbutamol (P 
0.020), indicating that there was a difference in the mean ADC
in the AP direction following bronchodilator therapy (Fig. 3C).
As shown in Table 2 and Fig. 5, Spearman correlation coeffi-
cients indicate that the postsalbutamol change in ADCP was
significantly correlated with the change in TLC (r  0.782,
P  0.011), FRC (r  0.806, P  0.007), and RV (r  0.733,
P  0.020).
DISCUSSION
We previously evaluated COPD ex-smokers using hyperpo-
larized 3He MRI before and after bronchodilator administration
and provided evidence of significant and visually obvious
regional improvements in 3He gas distribution following bron-
Fig. 1. Helium-3 (3He) MRI image analysis methodology. Subject is 74 yrs old female with Stage II chronic obstructive pulmonary disease [COPD; forced
expiratory volume in 1 s (FEV1)  47% predicted (47%pred), forced vital capacity (FVC)  92%pred, FEV1/FVC  39%, diffusing capacity of carbon monoxide
(DLCO) 20%pred]. 3He apparent diffusion coefficient (ADC) maps pre- and postsalbutamol, binary ventilation mask of lung regions of interest (ROI) with 3He
signal at both time points following registration of pre- and postsalbutamol ADC maps, 3He ADC maps for the previously ventilated (ADCP) lung ROI pre- and
postsalbutamol, and 3He ADC maps for newly ventilated (ADCN) lung ROI postsalbutamol with the computed tomography (CT) density masks to outline areas
with attenuation values 950 HU. CT images were acquired 19 mo following pre- and postsalbutamol imaging.
Table 1. Subject demographics
Parameter
Presalbutamol(SD)
[range] (n  10)
Postsalbutamol (SD)
[range] (n  10)
Significance of
Difference (P)*
Age yrs 70 (6) [61–77] –
Male sex 4 –
BMI kg/m2 25 (4) [18–30] –
FEV1 liter 1.11 (0.42) [0.63–2.06] 1.23 (0.49) [0.67–2.30] 0.007
FVC liter 2.67 (0.71) [1.52–4.06] 2.80 (0.86) [1.76–4.41] 0.20
FEV1/FVC 0.41 (0.09) [0.27–0.53] 0.45 (0.12) [0.32–0.70] 0.08
TLC liter 6.68 (1.21) [4.82–8.19] 6.20 (1.12) [4.71–7.74] 0.02
IC liter 2.10 (0.49) [1.39–3.09] 1.99 (0.60) [1.09–3.06] 0.23
FRC liter 4.56 (1.11) [3.14–5.97] 4.21 (1.04) [2.67–5.81] 0.02
RV liter 3.81 (0.89) [2.63–5.25] 3.31 (0.75) [2.16–4.36] 0.02
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; TLC, total lung capacity; IC, inspiratory capacity; FRC, func-
tional residual capacity; RV, residual volume. *Repeated measures ANOVA.
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chodilator therapy (18). Here, we extend these previous find-
ings and explore the relationship of regional hyperpolarized
3He ADC measurements in the pre- and postbronchodilator
lung ROI. We aimed to determine whether the ADCN regions
were different than lung ROI participating in ventilation before
bronchodilation, and based on previous histological findings
(41), we used the 3He MRI ADC as a surrogate measurement
of tissue microstructure. We made a number of observations
and report the following: 1) mean WL ADC did not change
postsalbutamol, 2) mean ADC in ADCN lung regions postsal-
butamol was not different than mean ADCP, 3) mean ADC in
ADCP lung regions was significantly different (improved)
postsalbutamol, and 4) ADC AP gradients significantly im-
proved postsalbutamol.
First, we observed no significant change in WL ADC mea-
surements following salbutamol administration, and this find-
ing suggests that the alveolar structures that are probed by the
3He gas postsalbutamol are not more emphysematous than the
other lung ROI probed by the 3He gas presalbutamol. In other
words, this finding indicates that the bronchodilator was deliv-
ered primarily to the more normal lung regions. However, the
3He ADC has been previously demonstrated to be sensitive to
gas trapping in the dependent lung regions (7), which may lead
to a reduction in the ADC measurement postbronchodilator.
Because we observed no change in WL ADC postsalbutamol,
we developed methods to determine regional ADC as a way to
tease apart the potential combinations of reduced hyperinfla-
tion and gas redistribution to lung ROI with greater emphyse-
matous destruction.
We applied these image processing methods and postsalbu-
tamol, observed no significant difference between mean ADC
in the ADCN and mean ADC in the ADCP lung, indicating that
the lung ROI that participated in gas distribution following
administration of salbutamol were not more emphysematous
than lung ROI participating in gas distribution before salbuta-
mol administration. These findings must be interpreted with an
understanding of the limitations of the relatively large voxel
size (3.2 mm  3.2 mm  30 mm) in this analysis and these
images reflect the contributions of 	70,000 alveoli, estimated
based on the mean size of a single, normal alveolus to be
4.2  106 cm3, as described previously (32). Additionally,
Table 2. Correlation between the postsalbutamol change in
ADC and the change in pulmonary function measurements
Parameter
Spearman Correlation Coefficients (r)
WL ADC (cm2/s) WL ADCP (cm2/s)
TLC liter 0.515 (0.133) 0.782 (0.011)
IC liter 0.139 (0.707) 0.285 (0.427)
FRC liter 0.636 (0.054) 0.806 (0.007)
RV liter 0.479 (0.166) 0.733 (0.020)
ADC, apparent diffusion coefficient; WL, whole lung; ADCP, previously
ventilated regions of interest ADC.
Fig. 2. 3He whole-lung (WL) ADC presalbutamol and postsalbutamol. Subject is a 64-yr-old male with Stage III COPD [presalbutamol: FEV1  38%pred,
FVC  73%pred, total lung capacity (TLC)  115%pred, functional residual capacity (FRC)  147%pred, residual volume (RV)  179%pred, DLCO  41%pred;
postsalbutamol: FEV1  43%pred, FVC  84%pred, TLC  110%pred, FRC  133%pred, RV  170%pred]. Pre- and postsalbutamol WL ADC maps with the
corresponding mean ADC measurement shown below for each image slice.
Fig. 3. Regional 3He MRI ADC. Mean WL ADC measurements, mean WL
ADC for the ADCP lung ROI, mean ADPP for the most anterior and posterior
slices, and the absolute change in ADCP for the most anterior to the most
posterior slice (AP) pre- and postsalbutamol for all subjects (A). Mean ADCP
pre- and postsalbutamol for the most anterior and most posterior slices. Error
bars are the SE (B). Mean AP for ADCP pre- and postsalbutamol. Error bars
are the SE (C).
654 LUNG MICROSTRUCTURE POSTBRONCHODILATOR IN COPD
J Appl Physiol • doi:10.1152/japplphysiol.01295.2011 • www.jappl.org
Downloaded from journals.physiology.org/journal/jappl at Univ Western Ontario (129.100.044.207) on March 4, 2020.
the contribution of subject motion between imaging time points
and the volume of gas within the lungs during the breath-hold
imaging may have contributed to measurement uncertainty.
Nevertheless, we have previously evaluated the ADC measure-
ment within 1 wk with no treatment (scan, 7-day rescan) (22)
and determined that the estimated standard uncertainty (SD) of
both the WL ADC and the center slice ROI ADC measurement
in Stage II and Stage III COPD subjects was 0.001 cm2/s,
indicating that the ADC measurement in subjects with moder-
ate-to-severe disease was remarkably reproducible. A previous
study evaluating asthma subjects using 3He MRI and multide-
tector CT demonstrated that there was a regional association
between 3He MRI ventilation abnormalities and CT measure-
ments of gas trapping (10). Although it is plausible in the
current study that emphysematous tissue destruction may have
reduced the tethering of the airways at forced expiration (36),
resulting in trapped gas and ventilation defects in severe COPD
subjects, our findings suggest that defect regions that become
ventilated in response to bronchodilators do not reflect more
severe emphysema. Moreover, these results indicate that the
bronchodilator acted on the obstructed small airways directly,
allowing improvements in gas trapping and regional hyperin-
flation, and not on airways obstructed due to surrounding
emphysema. As shown in Fig. 3, both emphysematous and
healthy regions of the lung participated in gas distribution
postsalbutamol. We must acknowledge that the very small
number of newly ventilated voxels in the postsalbutamol im-
ages may lead to biased ADC values due to a low signal-to-
noise ratio (SNR) (31), although this would have generated a
bias toward higher ADC, and this was not observed in the
current study. To minimize the potential for bias, we used a
morphological closing algorithm to remove the contribution of
small, isolated voxels to the mean ADC value, and a SNR
threshold 
15 for ADC generation was used as described
previously (31).
We also observed a statistically significant reduction (im-
provement) in mean ADCP postsalbutamol. This small but
significant improvement may be explained by both a reduction
in the physical size of the airspaces due to the increased
distribution of the 3He gas (thereby effectively diluting the
1-liter dose) and bronchodilator-induced reduction in lung
hyperinflation. To determine whether the significant change in
ADCP was related to a reduction in lung hyperinflation, we
compared the anatomical distribution of ADC values pre- and
postsalbutamol. As described previously (7), airspaces are less
compressible in COPD compared with healthy subjects in the
dependent lung, likely because of gas trapping. We detected a
statistically significant increase in AP and decreased mean
ADCP in the most posterior slice postsalbutamol, suggesting
that bronchodilator administration improved the expiratory
time constants, which in turn, allowed the dependent lung
regions to empty more completely. Moreover, as demonstrated
Fig. 4. Regional 3He MRI ADC. WL center slice 3He ADC maps pre- and
postsalbutamol, 3He ADC maps for ADCN lung ROI postsalbutamol, and CT
density masks to outline areas with attenuation values 950 HU for a
74-yr-old female and a 64-yr-old male, both with Stage III COPD. CT images
were acquired 15 mo following pre- and postsalbutamol imaging for the
74-yr-old subject and 28 mo following pre- and postsalbutamol imaging for the
64-yr-old subject.
Fig. 5. Correlations between the postsalbutamol change () in 3He ADCP and pulmonary function measurements. ADCP was correlated significantly with TLC
(r  0.782, P  0.011; r2  0.387, P  0.055; y  26.99  0.30; A); FRC (r  0.806, P  0.007; r2  0.604, P  0.008; y  23.13  0.19; B); and
RV (r  0.733, P  0.020; r2  0.379, P  0.039; y  28.91  0.31; C). Dotted lines represent the 95% confidence intervals for the regressions. L, liter.
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in our previous study (18), there was no bias for any measur-
able changes in the distribution of 3He gas postsalbutamol with
respect to image slice, indicating that the reduction in mean
ADCP within the dependent lung regions was not due to
increased gas distribution in these regions. The significant
correlation detected between the change in ADCP and changes
in TLC, FRC, and RV postsalbutamol lends support to the
hypothesis that the reduction in ADCP postsalbutamol was
related to a reduction in gas trapping.
We recognize that this work was limited by the small
number of subjects and the fact that the analysis was restricted
mainly to subjects with moderate-to-severe COPD. Therefore,
caution should be exercised in extrapolating these results to the
general COPD population and more specifically, to patients
with mild and very severe disease. An important limitation of
3He MRI is that large regions of the lung are not ventilated or
are poorly ventilated, preventing calculation of the ADC within
these regions, and this may be due to small airway occlusion,
mucous plugs, airway wall thickening and inflammation, se-
vere emphysema, or bullous disease. Another limitation is the
lack of a true reference standard for the measurement of
treatment effects in COPD, such as dyspnea scores and mea-
surements of exercise tolerance for direct comparison with 3He
MRI measurements to evaluate the clinical meaning of the
imaging changes. In other words, whether the changes in ADC
measures postsalbutamol are related to clinical, or symptom-
atic improvement remains to be established in a larger study.
The lack of validation by an imaging reference method, such as
CT or proton MRI with ultrashort TEs (UTE), is also a
limitation of this work. Clearly, the direct comparison of
functional and structural 3He MRI, proton UTE MRI, CT, and
symptomatic measurements will allow for a better understand-
ing of the improvements in 3He gas distribution observed after
bronchodilator administration. It must also be noted that 3He
MRI ADC provides structural information, not only at the scale
of the alveoli, probing emphysematous tissue destruction, but
also at the scale of the alveolar ducts and the respiratory and
terminal bronchioles (43); thus restriction to diffusion will
differ in each of these structures, and alveoli diffusion will be
more restricted than diffusion in the bronchioles. An important
point related to this is the issue of collateral ventilation. In
patients with emphysema, there is substantial collateral venti-
latory pathways (27), including the pores of Kohn, canals of
Lambert, and interbroncial communications of Martin. Al-
though with the very short diffusion times used in this study,
where the atoms are likely to be confined to the alveoli and
acinar structures, measurements of 3He diffusion over longer
times and distances are likely sensitive to collateral ventilation
paths (1, 42), which are significant in patients with emphy-
sema. A better understanding of collateral ventilation and
collateral pathways is required, and noninvasive imaging mea-
surements, such as 3He MRI ADC, may be useful for treatment
planning, such as bronchoscopic airway bypass, and evaluating
treatment effects. It is also important to note that study subjects
were provided training and instruction for inspiration breath-
hold scanning, and they performed practice breath-holds and
received coaching during breath-hold MRI. It is clear for all
imaging studies that standardization is required for reproduc-
ible and comparable breath-hold volumes, and this is critically
important for acute and chronic therapy repeated studies.
Another important consideration is the limited 3He MRI access
and the high cost of 3He gas that has, thus far, restricted
translation of this functional imaging method to specialized
MR physics centers. It is important to note the development of
hyperpolarized 129Xe MRI, a less expensive and more readily
available approach and a promising alternative with which
these reported findings can be tested directly.
In summary, this study demonstrated that 3He MRI provides
a noninvasive approach for the evaluation of regional structure-
function measurements after bronchodilator administration in
COPD subjects. Lung microstructure in ROI that participate in
gas distribution only after bronchodilator administration was
not more emphysematous than ROI participating in gas distri-
bution before bronchodilator use. We also demonstrated that
regional ADCs reflect significant changes in the AP gradient
following bronchodilator therapy, and this is possibly related to
a reduction in regional gas trapping. The regional evaluation of
hyperpolarized 3He MRI ADC provides insights into regional
lung microstructure for lung ROI that participate in 3He gas
distribution after bronchodilator administration.
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